EMERYVILLE, Calif.,
Dec. 27, 2022 /PRNewswire/ -- Amyris,
Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company
accelerating the world's transition to sustainable consumption
through its Lab-to-MarketTM technology platform today
announced that it has completed the negotiation of key financial
and business terms of the previously communicated strategic
transaction for the exclusive rights to supply two of Amyris'
ingredients.
The transaction is subject to antitrust review under the
Hart-Scott-Rodino Act ("HSR") with a standard waiting period of
thirty days. Accordingly, the transaction is expected to sign and
close early in the first quarter of 2023. Both parties have agreed
to confidentiality regarding further details about the transaction
during this period.
The transaction, with an expected value of over $500 million, is expected to follow a structure
similar to those completed by Amyris in 2021, and include an
exclusive worldwide license for the distribution, marketing and
selling of two Amyris ingredients. Amyris would continue to
develop, scale and manufacture the ingredients. In addition, the
parties are expected to enter a long-term R&D collaboration
partnership for the development of new molecules.
"We are pleased with the strong continued growth across our core
business. The power of our technology is evident, and we are very
excited about the potential of this new partnership and the
continued growth of the two ingredients," commented John Melo, President and Chief Executive
Officer. "This is our third transaction of this nature and what we
believe to be a strategic part of our business model for the value
creation of our technology."
About Amyris
Amyris (Nasdaq: AMRS) is a leading
synthetic biotechnology company, transitioning the Clean Health
& Beauty and Flavors & Fragrances markets to sustainable
ingredients through fermentation and the company's proprietary
Lab-to-MarketTM technology platform. This Amyris
platform leverages state-of-the-art machine learning, robotics and
artificial intelligence, enabling the company to rapidly bring new
innovation to market at commercial scale. Amyris ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris also owns and
operates a family of consumer brands that is constantly evolving to
meet the growing demand for sustainable, effective and accessible
products. For more information, please visit
http://www.amyris.com.
Amyris, the Amyris logo, and Lab-to-Market, are trademarks or
registered trademarks of Amyris, Inc. or its subsidiaries in the
U.S. and/or other countries.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding future events, such as Amyris'
expectations regarding the execution and closing of the strategic
transaction for two ingredients and the timing thereof; the timing
and outcome of HSR review; the final terms of the strategic
transaction including the potential long-term value thereof; future
supply and collaboration arrangements related to the strategic
transaction; the continued growth of Amyris' core business,
including the two ingredients related to the strategic transaction;
and strategic transactions of this nature forming part of Amyris'
business model for value creation. These statements are based on
management's current expectations and actual results and future
events may differ materially due to risks and uncertainties,
including risks related to Amyris' liquidity and ability to fund
operating and capital expenses, risks related to its financing
activities, risks related to potential delays or failures in
completing and integrating planned acquisitions, risks related to
potential delays or failures in development, regulatory approval,
launch, production and commercialization of products, risks related
to global inflation and policy measures undertaken to address
inflation, the COVID-19 pandemic and any other geopolitical events,
including Russia's invasion of Ukraine, resulting in
global economic, financial and supply chain disruptions that may
negatively impact Amyris' business operations and financial results
or cause market volatility, risks related to Amyris' reliance on
third parties particularly in the supply chain, and other risks
detailed from time to time in filings Amyris makes with the
Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a
result of new information, future events, or otherwise.
View original
content:https://www.prnewswire.com/news-releases/amyris-successfully-advances-strategic-transaction-301710137.html
SOURCE Amyris, Inc.